Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.08
MKGAY's Cash to Debt is ranked lower than
94% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. MKGAY: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
MKGAY' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 10000.00 Max: No Debt
Current: 0.08
Equity to Asset 0.34
MKGAY's Equity to Asset is ranked lower than
85% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MKGAY: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
MKGAY' s Equity to Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.47 Max: 0.61
Current: 0.34
0.27
0.61
Interest Coverage 7.13
MKGAY's Interest Coverage is ranked lower than
70% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.94 vs. MKGAY: 7.13 )
Ranked among companies with meaningful Interest Coverage only.
MKGAY' s Interest Coverage Range Over the Past 10 Years
Min: 0.64  Med: 5.63 Max: 9999.99
Current: 7.13
0.64
9999.99
F-Score: 4
Z-Score: 0.66
M-Score: -2.30
WACC vs ROIC
7.56%
9.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 14.35
MKGAY's Operating margin (%) is ranked higher than
68% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. MKGAY: 14.35 )
Ranked among companies with meaningful Operating margin (%) only.
MKGAY' s Operating margin (%) Range Over the Past 10 Years
Min: 2.84  Med: 11.02 Max: 17.91
Current: 14.35
2.84
17.91
Net-margin (%) 8.68
MKGAY's Net-margin (%) is ranked higher than
59% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. MKGAY: 8.68 )
Ranked among companies with meaningful Net-margin (%) only.
MKGAY' s Net-margin (%) Range Over the Past 10 Years
Min: 4.86  Med: 8.68 Max: 49.88
Current: 8.68
4.86
49.88
ROE (%) 8.44
MKGAY's ROE (%) is ranked higher than
55% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. MKGAY: 8.44 )
Ranked among companies with meaningful ROE (%) only.
MKGAY' s ROE (%) Range Over the Past 10 Years
Min: 3.86  Med: 9.09 Max: 56.55
Current: 8.44
3.86
56.55
ROA (%) 3.55
MKGAY's ROA (%) is ranked lower than
51% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. MKGAY: 3.55 )
Ranked among companies with meaningful ROA (%) only.
MKGAY' s ROA (%) Range Over the Past 10 Years
Min: 2.33  Med: 3.48 Max: 30.58
Current: 3.55
2.33
30.58
ROC (Joel Greenblatt) (%) 42.32
MKGAY's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. MKGAY: 42.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MKGAY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 8.06  Med: 29.55 Max: 52.81
Current: 42.32
8.06
52.81
Revenue Growth (3Y)(%) 4.80
MKGAY's Revenue Growth (3Y)(%) is ranked lower than
54% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. MKGAY: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MKGAY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 4.80 Max: 15.7
Current: 4.8
0
15.7
EBITDA Growth (3Y)(%) 11.70
MKGAY's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. MKGAY: 11.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MKGAY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 4.20 Max: 14
Current: 11.7
0
14
EPS Growth (3Y)(%) 25.10
MKGAY's EPS Growth (3Y)(%) is ranked higher than
77% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. MKGAY: 25.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MKGAY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 16.95 Max: 52.1
Current: 25.1
0
52.1
» MKGAY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-19)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MKGAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.91
MKGAY's P/E(ttm) is ranked lower than
56% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.66 vs. MKGAY: 30.91 )
Ranked among companies with meaningful P/E(ttm) only.
MKGAY' s P/E(ttm) Range Over the Past 10 Years
Min: 10.19  Med: 28.37 Max: 52.43
Current: 30.91
10.19
52.43
Forward P/E 12.80
MKGAY's Forward P/E is ranked higher than
64% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.86 vs. MKGAY: 12.80 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.91
MKGAY's PE(NRI) is ranked lower than
56% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.62 vs. MKGAY: 30.91 )
Ranked among companies with meaningful PE(NRI) only.
MKGAY' s PE(NRI) Range Over the Past 10 Years
Min: 10.19  Med: 28.38 Max: 51.95
Current: 30.91
10.19
51.95
Price/Owner Earnings (ttm) 20.19
MKGAY's Price/Owner Earnings (ttm) is ranked higher than
72% of the 259 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.02 vs. MKGAY: 20.19 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MKGAY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.01  Med: 13.57 Max: 23.48
Current: 20.19
3.01
23.48
P/B 0.81
MKGAY's P/B is ranked higher than
90% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. MKGAY: 0.81 )
Ranked among companies with meaningful P/B only.
MKGAY' s P/B Range Over the Past 10 Years
Min: 0.35  Med: 0.65 Max: 1.05
Current: 0.81
0.35
1.05
P/S 2.69
MKGAY's P/S is ranked higher than
50% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. MKGAY: 2.69 )
Ranked among companies with meaningful P/S only.
MKGAY' s P/S Range Over the Past 10 Years
Min: 0.59  Med: 1.95 Max: 7.95
Current: 2.69
0.59
7.95
PFCF 22.99
MKGAY's PFCF is ranked higher than
55% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.79 vs. MKGAY: 22.99 )
Ranked among companies with meaningful PFCF only.
MKGAY' s PFCF Range Over the Past 10 Years
Min: 7.13  Med: 15.87 Max: 88.72
Current: 22.99
7.13
88.72
POCF 15.74
MKGAY's POCF is ranked higher than
55% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.79 vs. MKGAY: 15.74 )
Ranked among companies with meaningful POCF only.
MKGAY' s POCF Range Over the Past 10 Years
Min: 5.87  Med: 11.15 Max: 52.28
Current: 15.74
5.87
52.28
EV-to-EBIT 12.48
MKGAY's EV-to-EBIT is ranked higher than
73% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.51 vs. MKGAY: 12.48 )
Ranked among companies with meaningful EV-to-EBIT only.
MKGAY' s EV-to-EBIT Range Over the Past 10 Years
Min: 2.9  Med: 16.35 Max: 114.3
Current: 12.48
2.9
114.3
EV-to-EBITDA 6.77
MKGAY's EV-to-EBITDA is ranked higher than
89% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. MKGAY: 6.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
MKGAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.7  Med: 7.40 Max: 41.9
Current: 6.77
1.7
41.9
Current Ratio 0.78
MKGAY's Current Ratio is ranked lower than
94% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MKGAY: 0.78 )
Ranked among companies with meaningful Current Ratio only.
MKGAY' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.60 Max: 2.24
Current: 0.78
0.78
2.24
Quick Ratio 0.50
MKGAY's Quick Ratio is ranked lower than
95% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MKGAY: 0.50 )
Ranked among companies with meaningful Quick Ratio only.
MKGAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.11 Max: 1.62
Current: 0.5
0.5
1.62
Days Inventory 173.42
MKGAY's Days Inventory is ranked lower than
76% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. MKGAY: 173.42 )
Ranked among companies with meaningful Days Inventory only.
MKGAY' s Days Inventory Range Over the Past 10 Years
Min: 162.19  Med: 220.43 Max: 272.47
Current: 173.42
162.19
272.47
Days Sales Outstanding 77.81
MKGAY's Days Sales Outstanding is ranked lower than
54% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. MKGAY: 77.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
MKGAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.5  Med: 77.81 Max: 102.54
Current: 77.81
66.5
102.54
Days Payable 172.03
MKGAY's Days Payable is ranked higher than
86% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.22 vs. MKGAY: 172.03 )
Ranked among companies with meaningful Days Payable only.
MKGAY' s Days Payable Range Over the Past 10 Years
Min: 132.67  Med: 159.34 Max: 172.03
Current: 172.03
132.67
172.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.29
MKGAY's Dividend Yield is ranked lower than
57% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. MKGAY: 1.29 )
Ranked among companies with meaningful Dividend Yield only.
MKGAY' s Dividend Yield Range Over the Past 10 Years
Min: 0.85  Med: 1.43 Max: 5.19
Current: 1.29
0.85
5.19
Dividend Payout 0.38
MKGAY's Dividend Payout is ranked lower than
56% of the 371 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. MKGAY: 0.38 )
Ranked among companies with meaningful Dividend Payout only.
MKGAY' s Dividend Payout Range Over the Past 10 Years
Min: 0.31  Med: 0.42 Max: 1.78
Current: 0.38
0.31
1.78
Dividend Growth (3y) 10.10
MKGAY's Dividend Growth (3y) is ranked higher than
57% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. MKGAY: 10.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MKGAY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 15
Current: 10.1
0
15
Forward Dividend Yield 1.28
MKGAY's Forward Dividend Yield is ranked lower than
56% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. MKGAY: 1.28 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.29
MKGAY's Yield on cost (5-Year) is ranked lower than
63% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. MKGAY: 1.29 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MKGAY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.85  Med: 1.43 Max: 5.19
Current: 1.29
0.85
5.19

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.41
MKGAY's Price/Projected FCF is ranked higher than
73% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. MKGAY: 1.41 )
Ranked among companies with meaningful Price/Projected FCF only.
MKGAY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.05  Med: 1.42 Max: 1.74
Current: 1.41
1.05
1.74
Price/Median PS Value 1.39
MKGAY's Price/Median PS Value is ranked lower than
66% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. MKGAY: 1.39 )
Ranked among companies with meaningful Price/Median PS Value only.
MKGAY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 0.89 Max: 1.55
Current: 1.39
0.26
1.55
Price/Peter Lynch Fair Value 1.70
MKGAY's Price/Peter Lynch Fair Value is ranked lower than
59% of the 173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. MKGAY: 1.70 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MKGAY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.71  Med: 1.54 Max: 4.07
Current: 1.7
0.71
4.07
Price/Graham Number 2.23
MKGAY's Price/Graham Number is ranked lower than
99.99% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. MKGAY: 2.23 )
Ranked among companies with meaningful Price/Graham Number only.
MKGAY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.95  Med: 1.97 Max: 6.19
Current: 2.23
0.95
6.19
Earnings Yield (Greenblatt) (%) 8.02
MKGAY's Earnings Yield (Greenblatt) (%) is ranked higher than
81% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MKGAY: 8.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MKGAY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.9  Med: 6.10 Max: 34.9
Current: 8.02
0.9
34.9
Forward Rate of Return (Yacktman) (%) 23.63
MKGAY's Forward Rate of Return (Yacktman) (%) is ranked higher than
81% of the 316 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. MKGAY: 23.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MKGAY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.2  Med: 24.10 Max: 55.8
Current: 23.63
12.2
55.8

More Statistics

Revenue(Mil) $14432
EPS $ 0.96
Beta1.33
Short Percentage of Float0.00%
52-Week Range $26.91 - 38.58
Shares Outstanding(Mil)387.77

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 16,296 16,843 17,004
EPS($) 2.04 2.21 2.39
EPS without NRI($) 2.04 2.21 2.39

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:MRK.Germany, MER.Switzerland, 0O14.UK,
Merck KGaA is a pharmaceutical and chemical company founded in 1668 in Darmstadt. It operates as a manufacturer of standard and specialty chemicals for the laboratory and industry. The Company researches drugs in the areas oncology and neurodegenerative as well as autoimmune and inflammatory diseases. The Company operate its businesses in four divisions: Merck Serono (prescription medicines), Consumer Health (over-the-counter pharmaceuticals), Performance Materials (high-tech chemicals) and Merck Millipore (products for pharmaceutical research and biotechnology).:. Within the Merck Serono division, the Company researches on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for flat screens and the pharmaceutical, food, cosmetics, packaging, and coatings.
» More Articles for MKGAY

Headlines

Articles On GuruFocus.com

More From Other Websites
Merck Builds on Leading Viral and Gene Therapy Service Offering with Capacity Expansion May 04 2016
Merck at SID: Materials for the Displays of Today and Tomorrow May 04 2016
Merck Expands Production Know-how to Deliver Full End-To-End Solution for Biopharma Industry May 02 2016
Annual General Meeting Approves Dividend Increase Apr 29 2016
Merck Annual General Meeting 2016: CEO Handover After Ten Successful Years Apr 29 2016
New Merck Products Bring Ease of Use to Single-Use Apr 27 2016
Merck Introduces First Multi-use Disposable Sterile Connectors for Biopharma at INTERPHEX 2016 Apr 26 2016
Merck Wins European Investor Relations Award Apr 25 2016
Merck Earns Accreditation for Quality Control of Culture Media Apr 19 2016
The Two Mercks Are Locking Horns in a Naming Trademark Spat Apr 18 2016
Merck to Present Data On Comparative Effectiveness of Rebif versus Oral Therapy at AAN Annual... Apr 14 2016
Merck Appoints Maya Martinez-Davis as Global Head of Oncology Apr 14 2016
Merck Makes Pioneering Technologies Gavi, Geri and Gems Available to Fertility Clinics Apr 11 2016
Merck and Sysmex Inostics Receive CE Mark Approval for Liquid Biopsy Test for Colorectal Cancer... Apr 06 2016
Merck and Pfizer Announce First Patient Treated in Phase III Combination Study with Avelumab and... Apr 05 2016
Merck’s CRISPR Epigenetic Activator Named to The Scientist’s Top 10 Innovation List Mar 29 2016
Merck Presents New Highlights at In-Cosmetics 2016: Make-up Trends, Innovative Protection and... Mar 29 2016
Merck Introduces IsoBag™ for Faster and Easier Transfer of Contact and Settle Plates Mar 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK